NSTE-ACS
Conditions
Interventions
A20:atorvastatin 20mg/d
A20+E10:atorvastatin 20mg/d combined with ezetimibe10mg/d
A40:atorvastatin 40mg/d
A40+E10:atorvastatin 40mg/d combined with ezetimibe 10mg/d
Sponsors
The First Affiliated Hospital of China Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All the subjects in the study were in patients aged >= 18 years in the Department of Cardiology, First Hospital Affiliated with China Medical University (Shen yang, China) from March 2018 to June 2019.
Exclusion criteria
Exclusion criteria: 1. had a history of previous statin or ezetimibe therapy; 2. had a history of statin-induced myopathy or serious hypersensitivity reaction to statins and /or a history of hypersensitivity to any ezetimibe components; 3. had severe congestive cardiac failure (New York Heart Association class IIIb or IV); 4. had current active liver disease (alanine aminotransferase > 2 times the upper limit of normal [ULN]) or severe hepatic impairment, uncontrolled hypothyroidism, unexplained creatine kinase >1 ULN before enrollment or serum creatinine >176 mmol/l (2.0 mg/dl). 5. Women who were pregnant, breastfeeding, or of childbearing potential but not using contraception were also excluded, or other comorbidities, including infection, systemic immune diseases, pericarditis and malicious tumour.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| lipoprotein-associated phospholipase A2;VCAM; | — |
Secondary
| Measure | Time frame |
|---|---|
| periprocedural myocardial injury;Major adverse cardiovascular events;statin-related myopathy;liver enzyme elevation; | — |
Countries
China
Contacts
Public ContactDalin Jia
The First Affiliated Hospital of China Medical University
Outcome results
None listed